Vimarsana
Biggest News Aggregation in the World

Page 8 - Comparative Effectiveness News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Comparative Effectiveness. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Comparative Effectiveness Today - Breaking & Trending Today

AHA Scientific Sessions 2022 Program, Late Breakers Announced - Vimarsana News

AHA Scientific Sessions 2022 Program, Late Breakers Announced

The American Heart Association (AHA) Scientific Sessions 2022 in Chicago, and virtually, is set for November 5-7 at McCormick Place. Highly-anticipated clinical trial breakthroughs and discoveries of the year will be offered in both late-breaking scientific sessions and featured science sessions.

Despite Benefits, Extended-Interval Pembro Uptake Remains Low - Vimarsana News

Despite Benefits, Extended-Interval Pembro Uptake Remains Low

New findings may ease lingering doubts about the therapeutic equivalence and safety of extended-interval vs standard dosing of pembrolizumab.

"Bending the Curve": What Really Drives Health Care Spending - Vimarsana News

"Bending the Curve": What Really Drives Health Care Spending

Contrary to their stated intent, the health care reform bills passed by the House and Senate would sub­stantially increase health care spending if either became law. Based on a fundamental misunderstanding of what drives health care spending, these bills exacerbate many of the inefficiencies in the U.S. health care system, particu­larly those that drive spending upward. While an increased prevalence of disease, the third-party payment system, technological change, and waste and fraud are likely con­tributing to increased health care spending, the main prob­lem is a pricing system that insu...

Trial Supports Hypofractionated Radiotherapy in Uterine Cancer - Vimarsana News

Trial Supports Hypofractionated Radiotherapy in Uterine Cancer

A pilot study found that delivery of approximately the same dose over just 2.5 weeks, known as hypofractionation, had good short-term toxicity outcomes.

NIH Study Compares Four Commonly Used Type 2 Diabetes Medications - Vimarsana News

NIH Study Compares Four Commonly Used Type 2 Diabetes Medications

Liraglutide and insulin glargine performed the best out of 4 commonly used medications to maintain blood glucose levels in the recommended range.

Source: empr.com